In this week's Tell Me Why episode, Dr. Feroza Dawood, Obstetrician and Gynecologist, explains to podcast host Maria Botros the dangers of respiratory syncytial virus (RSV) and the benefits of a ...
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
GlobalData on MSN16h
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trialShionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback